Challenges Remain in the Treatment Landscape for MyelofibrosisApril 4th 2020
Ruben Mesa, MD, discusses the current challenges in the treatment landscape for researchers treating myelofibrosis (MF) and how a greater understanding of why patients relapse will help investigators overcome these challenges.
Mesa Advises Community Oncologists on JAK Inhibitors for Intermediate-Risk MyelofibrosisNovember 22nd 2019
Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, gives advice on using the JAK inhibitors ruxolitinib and fedratinib in the community setting for patients with intermediate-risk myelofibrosis.<br />
Considering Fedratinib or Ruxolitinib in the Frontline Setting for Treatment of MyelofibrosisSeptember 24th 2019
Ruben Mesa, MD, discusses his experience with fedratinib since its FDA approval for the treatment of patients with myelofibrosis. The agent is compared across trials with ruxolitinib, which has been approved for several years in this space.
JAKARTA-2 Reanalysis Demonstrates Activity With Fedratinib in Myelofibrosis After Ruxolitinib FailureJune 27th 2019
Ruben Mesa, MD, discusses the results from a reanalysis of the phase II JAKARTA-2 study in patients with myelofibrosis (MF) who received a previous treatment of ruxolitinib (Jakafi) and failed treatment.